NoRD Bio

NoRD Bio is a precision medicine and diagnostics company based in Cambridge, Massachusetts, specializing in ultra-deep sequencing and multi-omic analysis of cell-free DNA (cfDNA). Founded by a team of experts from the Broad Institute and Dana-Farber Cancer Institute, the company utilizes its proprietary SmartRD platform and AI/ML algorithms to monitor tumor evolution, detect minimal residual disease (MRD), and identify early drivers of cancer. NoRD Bio provides high-sensitivity epigenetic and genetic profiling services to pharmaceutical and biotechnology companies to optimize clinical trials, improve patient stratification, and support the development of personalized therapies. The company's mission is to transform cancer care through non-invasive, cost-effective diagnostic solutions that enable earlier detection and more precise monitoring of disease progression.